Diazoxide Linked to Lung/Heart Problems in Infants
Diazoxide and Pulmonary Hypertension
The FDA claims to have found 11 reports of infants with pulmonary hypertension while taking diazoxide. These findings were recorded in the FDA Adverse Event Reporting System started in 1973, when diazoxide was first approved.
In each of these cases, pulmonary hypertension had subsided as soon as diazoxide was stopped. Pulmonary hypertension is the occurrence of high blood pressure that damages the lungs and heart.
Signs of pulmonary hypertension in infants resulting from the use of diazoxide include respiratory difficulty such as grunting, unnatural chest movements, flaring nostrils, fast breathing, trouble feeding, or bluish color in the skin and lips.
Infants high at risk for meconium aspiration syndrome, respiratory distress syndrome, transient tachypnea, pneumonia, sepsis, congenital diaphragmatic hernia, and congenital heart disease should be especially cautious when taking this drug.
More about Diazoxide
Hypoglycemia is a condition in which the body has abnormally low levels of blood sugar. Hypoglycemia is not a disease alone, but a sign of further health problems. Diazoxide is an antihypoglycemia drug used in treating hypoglycemic patients.
Visit the U.S. Food and Drug Administration for more information about the recent findings on diazoxide and its link to pulmonary hypertension.